Freedom of Information request on the product Alemtuzumab (FOI 22/771)
Published 27 March 2023
© Crown copyright 2023
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-27-june-2022/freedom-of-information-request-on-the-product-alemtuzumab-foi-22771
FOI 22/771
30th June 2022
Dear
Alemtuzumab is authorised as Lemtrada for multiple sclerosis.
Alemtuzumab was previously authorised as MabCampath for B-cell chronic lymphocytic leukaemia but the licence was withdrawn in 2012. The link below provides further information:
Information regarding the previously authorised use of MabCampath is available at the link below
https://www.ema.europa.eu/en/medicines/human/EPAR/mabcampath
Use of alemtuzumab in transplant patients would be unlicensed use.
Kind regards,
FOI Team
Vigilance and Risk Management of Medicines Division